Print Page     Close Window     

Investors & Media

Corporate Profile

Seres Therapeutics, Inc. is a microbiome therapeutics platform company developing a novel class of biological drugs, which we refer to as Ecobiotic microbiome therapeutics, that are designed to restore health by repairing the function of a dysbiotic microbiome. The Company’s lead product candidate, SER-109, is intended to prevent further recurrences of Clostridium difficile infection (CDI), a debilitating infection of the colon, and, if approved by the FDA, could be a first-in-field drug. Using its... More

Recent NewsMore
Seres Therapeutics Strengthens Board of Directors with Appointment of Meryl Zausner, Experienced Biopharmaceutical Financial Leader
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Sep. 4, 2018-- Seres Therapeutics, Inc. (Nasdaq:MCRB) today announced the appointment of Meryl Zausner, a seasoned biopharmaceutical executive, to its Board of Directors. Ms. Zausner brings decades of financial and operational leadership experience in the pharmaceutical industry. “Meryl Zausner is a highly accomplished financial and strategic leader, and I am delighted to welcome her to the Seres Board,” ... 
Seres Therapeutics Reports Second Quarter Financial Results and Provides Operational Updates
- Company preparing to initiate SER-287 Phase 2b study for ulcerative colitis - - Initiation of SER-401 clinical study expected in patients with metastatic melanoma treated with checkpoint inhibitors by year end - - Recent Seres R&D event highlighted microbiome scientific leadership across several clinical and preclinical programs - - Conference call at 8:30 a.m. ET today - CAMBRIDGE, Mass.--(BUSINESS WIRE)-... 
Seres Therapeutics to Host Second Quarter 2018 Financial Results and Operational Progress Conference Call and Webcast on August 2, 2018
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Jul. 25, 2018-- Seres Therapeutics, Inc. (NASDAQ:MCRB) today announced that management will host a conference call and live audio webcast on August 2, 2018 at 8:30 a.m. ET to discuss second quarter 2018 financial results and provide a general business update. To access the conference call, please dial 844-277-9450 (domestic) or 336-525-7139 (international) and reference the conference ID number 818... 
Download DocumentationCorporate Presentation

There are currently no upcoming events scheduled.
Stock Quote
 - 0.22 (2.78%)
09/25/18 4:00 p.m. ET
Refresh quote
E-mail Alerts
Sign up to receive e-mail alerts whenever Seres Therapeutics, Inc. posts new information to the site. Just enter your e-mail address and click Submit.
Request Information

Obtain investor relations information by contacting us.

Data provided by Nasdaq. Minimum 15 minutes delayed.

© Seres Therapeutics. All Rights Reserved.